Treatment of Stiff Person Syndrome with Insidious Onset and Chronic Disease Course
Clinical Scenario
This protocol applies to Stiff Person Syndrome presenting with a gradual, insidious onset that progresses over months and settles into a stable, chronic course — with mild to moderate functional impairment. Exacerbations may occur against this background of persistent disease.
Insidious onset
Chronic course
Mild–moderate impairment
Treatment Approach
Symptomatic control of stiffness and spasms forms the foundation of management, with an oral benzodiazepine as the primary agent. Depending on the individual clinical picture, additional agents and targeted focal interventions may be incorporated. Where immune mechanisms are active, first-line immunotherapy can deliver a rapid and meaningful response and may also serve as ongoing maintenance therapy in chronic cases. The complete sequencing, full range of options, and clinical decision criteria are in the structured protocol.
Treatment Goals
- Meaningful reduction in stiffness and frequency of spasms
- Improved performance on timed functional activities
- Decrease in relevant antibody titres as a marker of immunotherapy response
References
DOI: 10.1002/mdc3.12629
- Most frequently, there is an insidious onset with a progression over months and a subsequent stable, chronic disease course, but there may be exacerbations.
- Insidious onset, Chronic course, Mild to moderate impairment
- Symptomatic treatment typically involves benzodiazepines (e.g. clonazepam, 1-6 mg/d, or diazepam, 5–50 mg/d).
- Botulinum toxin injections can alleviate focal stiffness and spasms and are used to avoid contractures or subluxations.
- “First line” immunotherapy (corticosteroids, plasma exchange, intravenous immunoglobulins) can bring about a rapid impact on immune dysregulation and is therefore often used to start treatment, but can also be used as maintenance therapy in chronic cases if proven beneficial.
View source ↗